Investigational Intratumoral Cancer Immunotherapy

OncoSec awarded “Best Technology Scientific Abstract” by the Society of Interventional Oncology

TAVO™ Monotherapy Results in Metastatic Melanoma Highlighted in Annals of Oncology

News & Events

Designed to Arm the Immune System to Fight Cancer

We are investigating the potential for our lead product candidate, TAVO, through the intratumoral administration of IL-12, to stimulate systemic immune response and to become an innovative and potentially transformative therapy option for the treatment of cancer.

Clinical Pipeline

Our core technology platform continues to advance through clinical trials for various cancers

Learn More


Our plasmid DNA delivery platform is designed to boost the body’s immune system to target and attack cancer

Learn More


We have a track record of establishing, operating and evolving high-performance partnerships globally

Learn More